What is the recommended treatment for respiratory syncytial virus (RSV) infection?

Treatment for RSV Infection

For most RSV infections, supportive care with hydration and oxygenation is the only treatment—there is no effective antiviral therapy for routine use. 1, 2

Acute Treatment Approach

General Population (Infants and Children)

Supportive care remains the cornerstone of RSV management, as evidence-based guidelines consistently demonstrate no effective specific treatment for RSV lower respiratory tract infection. 2

• Hydration and oxygenation are the primary interventions for hospitalized children 2
• Supplemental oxygen should be provided when clinically indicated 3
• High-flow nasal cannula appears beneficial in severe cases 1
• Mechanical ventilation may be necessary for critically ill patients 1
• Minimal intervention approach is preferred—avoid treatments with no proven efficacy 4
• Nutritional support should be ensured in hospitalized children 4

High-Risk Hematologic/Immunocompromised Patients

For allogeneic hematopoietic stem cell transplant (HSCT) recipients and leukemia patients with RSV lower respiratory tract disease, specific antiviral therapy may be considered:

• Aerosolized ribavirin: 2 g for 2 hours every 8 hours OR 6 g over 18 hours daily for 7-10 days 5
• Systemic ribavirin: 10-30 mg/kg body weight in 3 divided doses (oral preferred; IV if unable to take oral) 5
• Combination therapy: Ribavirin may be combined with IVIG or anti-RSV-enriched antibody preparations in allogeneic HSCT patients with RSV LRTD or at high risk for progression 5

Important monitoring for ribavirin therapy:

• Aerosolized form: Monitor for claustrophobia, bronchospasm, nausea, conjunctivitis, and declining pulmonary function 5
• Systemic form: Monitor for hemolysis, abnormal liver function tests, and declining renal function 5
• Environmental precautions: Protect pregnant healthcare workers from exposure due to teratogenic effects 5

Palivizumab for treatment (15 mg/kg IV) might be considered only in very young (<2 years) allogeneic HSCT patients with LRTD or at high risk for progression, though evidence is limited and cost is prohibitive 5

Prevention Strategies

Prophylaxis for High-Risk Infants

Palivizumab (monthly injections) is indicated for specific high-risk groups during RSV season:

Maximum 5 doses for:

• Infants <24 months with chronic lung disease (CLD) requiring medical therapy (oxygen, bronchodilators, diuretics, or corticosteroids) within 6 months before RSV season 5
• Infants <24 months with hemodynamically significant congenital heart disease (CHD) receiving medication for congestive heart failure, moderate-to-severe pulmonary hypertension, or cyanotic heart disease 5
• Infants with neuromuscular disease or congenital airway abnormalities that compromise respiratory secretion handling 5
• Premature infants born ≤31 weeks 6 days gestation 5

Maximum 3 doses for:

• Premature infants 32 weeks 0 days through 34 weeks 6 days gestation with at least one risk factor (attends childcare OR has sibling <5 years in household) AND born within 3 months before or during RSV season 5
• These infants receive prophylaxis only until 90 days of age 5

Post-cardiac surgery consideration: Administer additional dose (15 mg/kg) after cardiopulmonary bypass once patient is medically stable, as serum concentrations decrease by 58% 5

Newer Prevention Options

Nirsevimab (long-acting monoclonal antibody) is now available and preferred over palivizumab for broader infant populations:

• Recommended for all infants <12 months during RSV season 4, 6
• Extended half-life allows single-dose administration 3, 4

Maternal vaccination during pregnancy reduces severe RSV in newborns with efficacy equivalent to monoclonal antibodies 4

Adult vaccination (≥60 years) with RSVPreF3, RSVpreF, or mRNA-1345 is the most effective pharmacological prevention for elderly populations 7, 8

Non-Pharmacologic Prevention

All high-risk infants should:

• Avoid crowds and exposure to infected individuals 5
• Restrict group childcare participation during RSV season when feasible 5
• Practice careful hand hygiene (family and caregivers) 5
• Avoid tobacco smoke exposure completely 5
• Receive influenza vaccine (starting at 6 months) and age-appropriate immunizations 5
• Encourage breastfeeding (though specific protective effect against RSV is conflicting) 5

Special Situations

• Breakthrough RSV infection during prophylaxis: Continue monthly palivizumab until maximum doses reached (3 or 5 depending on indication), as multiple RSV strains may co-circulate 5
• Hospital discharge during RSV season: Administer first palivizumab dose 48-72 hours before discharge or promptly after 5
• Scheduled dose while hospitalized: Continue on schedule even if patient is hospitalized 5

Common Pitfalls

• Do not use palivizumab for hemodynamically insignificant heart disease (small VSD, ASD, mild coarctation, PDA, uncomplicated aortic stenosis) 5
• Do not routinely use palivizumab in cystic fibrosis patients—insufficient evidence 5
• Avoid ineffective interventions in hospitalized children with established RSV disease 4
• Withholding ribavirin may be appropriate for stable leukemia/HSCT patients after careful risk assessment 5